A-Control group (PBS/ISA-51)

- Week 9
- Week 15 / Week 16
- Week 19 / Week 27 / Week 32
- Week 45

B-TNF-K group (TNF-K/ISA-51)

- Sub-group I
  - Week 9
  - Week 15
  - Week 16
  - Week 19 / Week 27 / Week 32
  - Week 45

- Sub-group II
  - Week 9
  - Week 15
  - Week 16
  - Week 19 / Week 27

- Sub-group III
  - Week 9
  - Week 15
  - Week 16
  - Week 19 / Week 27 / Week 32
  - Week 45

C- infliximab group (weekly IP injections, from w15 to w27)

- Week 9
- Week 15
- Week 16
- Week 19
- Week 27
- Week 32
- Week 45

Supplemental 1- TNFK immunization protocol scheme

Long-term follow-up of the experiment is represented by horizontal arrow with time expressed in week (from week 9, w9, to week 45, w45). Slashes represent discontinuation of time. A- Control group treated with PBS/ISA-51; B- TNF-K group; C- Intermittent infliximab group. The follow-up for each group (PBS, TNF-K and infliximab) is represented by a larger black lign, with vertical black arrows at each time where treatment was given. IP injections, intraperitoneal injections.